Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bispecific egfr/igfir binding molecules

An IGF-IR, binding technology, applied in the direction of peptide/protein components, growth factors/inducible factors, anti-receptors/cell surface antigens/cell surface determinant immunoglobulins, etc.

Inactive Publication Date: 2012-05-02
BRISTOL MYERS SQUIBB CO
View PDF32 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Although targeted monotherapy is initially effective in treating cancer, treatment resistance often subsequently develops, possibly due to upregulation of other signaling cascades (see, eg, Nahta R et al., Breast Cancer Res. 20068(6): 215 and Horn L et al., Clin Lung Cancer.20078: S68-73)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific egfr/igfir binding molecules
  • Bispecific egfr/igfir binding molecules
  • Bispecific egfr/igfir binding molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0361] Example 1: Western Assay in Cells for Screening for −+EGFR Activity

[0362] Developed an In Cell Western assay to screen various 10 The ability of Fn3 monoclonals to inhibit EGFR activity, thus identifying the ability to interact with IGF1R 10Fn3 binders ligated to construct E / I binders. In-cell Western assays were also used to screen and measure specific E / I 10 Relative potency of Fn3 binders. Two in-cell Western assays were developed to measure 1) inhibition of EGF-stimulated EGFR phosphorylation or 2) inhibition of EGF-stimulated ERK phosphorylation. For A431 epidermoid carcinoma or FaDu head & neck carcinoma cells, cells were seeded at 24,000 cells / well into poly-D-lysine-coated 96-well microtiter plates (Becton Dickinson, Franklin Lakes, NJ) medium and allow them to attach overnight. Cells were washed once and then incubated in serum-free medium for 24 hours. Next, based on 10 Serial dilutions of conjugates of Fn3 were applied to cells and incubated for 2-3...

Embodiment 2

[0364] Example 2: Based on 10 Expression of Fn3 binders

[0365] Covalently link EGFR binding using a glycine-serine linker 10 Fn3 binding to IGFIR 10 Fn3, generated from 10 Fn3 dimers, each of which 10 The Fn3 domain binds different targets, resulting in E / I binders. IGFIR binding 10 Fn3(I1) was previously described as SEQ ID NO: 226 in PCT Publication No. WO 2008 / 066752. Two novel EGFR binding agents were identified by screening an RNA-protein fusion library for binders of EGFR-Fc (R&D Systems, Minneapolis, MN) as described in PCT Publication No. WO 2008 / 06675 10 Fn3 (E2 and El). The following examples describe the use of various His-tagged 10 E / I binders of Fn3 (non-PEGylated): E2-GS10-I1 (SEQ ID NO:25), E1-GS10-I1 (SEQ ID NO:31), I1-GS10-E1 (SEQ ID NO: 28), and the results obtained with I1-GS10-E2 (SEQ ID NO: 22).

[0366] The following examples also describe the use of the following PEGylated, His-tagged 10 Results obtained for E / I conjugates of Fn3: E1-GS10-I1...

Embodiment 3

[0373] Embodiment 3: based on 10 PEGylation of E / I binders of Fn3

[0374] Fibronectin-based multivalent scaffold proteins (such as those based on 10 E / I binder of Fn3) PEGylation. To allow PEGylation, the modification is usually made near the C-terminus of the protein by single point mutation of an amino acid (usually serine) to cysteine. PEGylation of proteins at single cysteine ​​residues is achieved by mixing and incubating derivatized PEG reagents with protein solutions to conjugate various maleimide-derivatized PEG forms. Proceeding and confirmation of the PEGylation coupling reaction can be confirmed by SDS-PAGE and / or SE-HPLC to separate the non-PEGylated protein from the PEGylated protein.

[0375] For example, construct E2-GS10-I1 (SEQ ID NO: 25) was PEGylated by replacing serine at position 221 with cysteine. The resulting construct, SEQ ID NO: 56, was then coupled to a maleimide derivatized 40 kDa branched PEG (NOF America Corporation, White Plains, NY). The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing that has been submitted via the EFS Network and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 23, 2009, is named COTH52WO.txt and is 552,529 bytes in size. [0003] related application [0004] This application claims U.S. Provisional Patent Application Nos. 61 / 200,164, filed November 24, 2008; 61 / 200,282, filed November 26, 2008; 61 / 212,966, filed April 17, 2009; May 14, 2009 61 / 178,279 filed; and 61 / 227,330 filed July 21, 2009, which are hereby incorporated by reference in their entirety. [0005] introduce [0006] The present invention relates to EGFR binding domains and bispecific molecules comprising an EGFR binding domain and a unique IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and vec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/78C07K16/28
CPCC07K2318/20C07K2317/31C07K2317/34C07K16/2863C07K14/78C07K2319/30C07K14/475A61K38/39A61P35/00A61P43/00A61K39/3955A61K45/06A61K2039/505C07K2317/92
Inventor 斯图尔特.伊曼纽尔琳达.恩格尔雷.坎普豪森马丁.C.赖特金格.C.拉克斯特劳马科.戈塔蒂斯琼.卡博尼
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com